Please login to the form below

Not currently logged in
Email:
Password:

Novartis in health technology assessment trial with NICE

Novartis is collaborating with the UK's medicines agency, the National Institute of Health and Clinical Excellence on the joint design of a late-stage clinical trial to assess efficacy and health economics of a new drug

According to the UK newspaper The Financial Times, Swiss-headquartered Novartis has collaborated with the UK's medicines agency, the National Institute of Health and Clinical Excellence (NICE) on the joint design of a late-stage clinical trial.

According to the 17 December article, NICE will charge a fee for informing Novartis which criteria will form the basis of its decision to advise the NHS whether to buy the medicine once it is launched.

In an interview with the FT, Joe Jimenez, Novartis' head of pharmaceuticals, said: "This is about identifying the impact of the drug and the evidence of impact. Input at an early stage gives us the evidence to speed our drug to market. We're looking at more innovative ways to stand behind our drugs."

In November 2007, Novartis consulted with NICE on the design of the phase III trial for the drug, which is currently named Novartis 001.

According to the FT, the results of the trial are expected within a year.

19th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics